Cargando…
A Perspective on COVID-19 Management
A novel coronavirus—Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2)—outbreak correlated with the global coronavirus disease 2019 (COVID-19) pandemic was declared by the WHO in March 2020, resulting in numerous counted cases attributed to SARS-CoV-2 worldwide. Herein, we discuss current...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8070140/ https://www.ncbi.nlm.nih.gov/pubmed/33918624 http://dx.doi.org/10.3390/jcm10081586 |
_version_ | 1783683400960311296 |
---|---|
author | Pavelić, Krešimir Kraljević Pavelić, Sandra Brix, Bianca Goswami, Nandu |
author_facet | Pavelić, Krešimir Kraljević Pavelić, Sandra Brix, Bianca Goswami, Nandu |
author_sort | Pavelić, Krešimir |
collection | PubMed |
description | A novel coronavirus—Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2)—outbreak correlated with the global coronavirus disease 2019 (COVID-19) pandemic was declared by the WHO in March 2020, resulting in numerous counted cases attributed to SARS-CoV-2 worldwide. Herein, we discuss current knowledge on the available therapy options for patients diagnosed with COVID-19. Based on available scientific data, we present an overview of solutions in COVID-19 management by use of drugs, vaccines and antibodies. Many questions with non-conclusive answers on the measures for the management of the COVID-19 pandemic and its impact on health still exist—i.e., the actual infection percentage of the population, updated precise mortality data, variability in response to infection by the population, the nature of immunity and its duration, vaccine development issues, a fear that science might end up with excessive promises in response to COVID-19—and were raised among scientists. Indeed, science may or may not deliver results in real time. In the presented paper we discuss some consequences of disease, its detection and serological tests, some solutions to disease prevention and management, pitfalls and obstacles, including vaccination. The presented ideas and data herein are meant to contribute to the ongoing debate on COVID-19 without pre-selection of available information. |
format | Online Article Text |
id | pubmed-8070140 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-80701402021-04-26 A Perspective on COVID-19 Management Pavelić, Krešimir Kraljević Pavelić, Sandra Brix, Bianca Goswami, Nandu J Clin Med Review A novel coronavirus—Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2)—outbreak correlated with the global coronavirus disease 2019 (COVID-19) pandemic was declared by the WHO in March 2020, resulting in numerous counted cases attributed to SARS-CoV-2 worldwide. Herein, we discuss current knowledge on the available therapy options for patients diagnosed with COVID-19. Based on available scientific data, we present an overview of solutions in COVID-19 management by use of drugs, vaccines and antibodies. Many questions with non-conclusive answers on the measures for the management of the COVID-19 pandemic and its impact on health still exist—i.e., the actual infection percentage of the population, updated precise mortality data, variability in response to infection by the population, the nature of immunity and its duration, vaccine development issues, a fear that science might end up with excessive promises in response to COVID-19—and were raised among scientists. Indeed, science may or may not deliver results in real time. In the presented paper we discuss some consequences of disease, its detection and serological tests, some solutions to disease prevention and management, pitfalls and obstacles, including vaccination. The presented ideas and data herein are meant to contribute to the ongoing debate on COVID-19 without pre-selection of available information. MDPI 2021-04-09 /pmc/articles/PMC8070140/ /pubmed/33918624 http://dx.doi.org/10.3390/jcm10081586 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Pavelić, Krešimir Kraljević Pavelić, Sandra Brix, Bianca Goswami, Nandu A Perspective on COVID-19 Management |
title | A Perspective on COVID-19 Management |
title_full | A Perspective on COVID-19 Management |
title_fullStr | A Perspective on COVID-19 Management |
title_full_unstemmed | A Perspective on COVID-19 Management |
title_short | A Perspective on COVID-19 Management |
title_sort | perspective on covid-19 management |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8070140/ https://www.ncbi.nlm.nih.gov/pubmed/33918624 http://dx.doi.org/10.3390/jcm10081586 |
work_keys_str_mv | AT pavelickresimir aperspectiveoncovid19management AT kraljevicpavelicsandra aperspectiveoncovid19management AT brixbianca aperspectiveoncovid19management AT goswaminandu aperspectiveoncovid19management AT pavelickresimir perspectiveoncovid19management AT kraljevicpavelicsandra perspectiveoncovid19management AT brixbianca perspectiveoncovid19management AT goswaminandu perspectiveoncovid19management |